John Neis - 12 Dec 2025 Form 4 Insider Report for Cellectar Biosciences, Inc. (CLRB)

Role
Director
Signature
/s/ Christina Blakley, attorney-in-fact for John Neis
Issuer symbol
CLRB
Transactions as of
12 Dec 2025
Net transactions value
-$732
Form type
4
Filing time
16 Dec 2025, 18:00:11 UTC
Previous filing
18 Feb 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
NEIS JOHN Director C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK /s/ Christina Blakley, attorney-in-fact for John Neis 16 Dec 2025 0001167426

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLRB Common Stock Sale $732 -198 -95% $3.70 10 12 Dec 2025 See Footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.631 to $3.70, inclusive. The reporting person has provided to the Issuer, and undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnote (1) to this Form 4.
F2 This number has been adjusted for (i) the one-for-thirty (1:30) reverse stock split effected by the Issuer on June 24, 2025, (ii) the one-for-ten (1:10) reverse stock split effected by the Issuer on July 21, 2022, and (iii) the one-for-ten (1:10) reverse stock split effected by the Issuer on July 16, 2018.
F3 These securities are held by Advantage Capital Wisconsin Partners I, Limited Partnership. Venture Investors LLC is the submanager and special limited partner of Advantage Capital Wisconsin Partners I, Limited Partnership. The investment decisions of Venture Investors LLC are made collectively by five managers, including the reporting person. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest herein.